The DOI matches its Crossref record.
NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case???control studies conducted in the general population
Abstract
The NAT2 gene is involved in phase II detoxification of aromatic monoamines, a class of known bladder carcinogens. Certain allelic combinations result in the slow acetylation phenotype, which is thought to increase bladder cancer risk. We conducted a meta-analysis of all identifiable published case-control studies conducted in the general population that had examined the relationship of acetylation status and bladder cancer risk (22 studies, 2496 cases, 3340 controls). Using meta-analysis techniques that employed weighting based on individual-study variation, slow acetylators had an approximately 40% increase in risk compared with rapid acetylators [odds ratio (OR) 1.4, 95% confidence interval (CI) 1.2-1.6]. Statistical tests indicated, however, that pooling of all studies, or of studies conducted in Caucasian populations, hid potentially important heterogeneity in the individual study results, and suggested that the relationship of NAT2 slow acetylation and bladder cancer risk might differ by geographical region. Studies conducted in Asia generated a summary OR of 2.1 (CI 1.2-3.8), in Europe, a summary OR of 1.4 (CI 1.2-1.6), and in the USA, a summary OR of 0.9 (CI 0.7-1.3). Among European studies, the relationship between NAT2 slow acetylation and bladder cancer risk did not differ by method used to assess acetylation status (older drug-based phenotyping methods: 10 studies, OR 1.5, CI 1.2-1.8; more recent NAT2 genotyping methods: four studies, OR 1.4, CI 1.1-1.7). Our results suggest that in most populations studied to date, NAT2 slow acetylation status is associated with a modest increase in bladder cancer risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer
Broberg, K., Björk, J., Paulsson, K., Höglund, M., & Albin, M. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi063 · Cited by 255
Genetic Polymorphism in N-Acetyltransferase (NAT): Population Distribution of NAT1 and NAT2 Activity
Walker, K., Ginsberg, G., Hattis, D., Johns, D. O., Guyton, K. Z., & Sonawane, B. (2009) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400903158383 · Cited by 140
N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort
Pesch, B., Gawrych, K., Rabstein, S., Weiss, T., Casjens, S., Rihs, H.-P., Ding, H., Angerer, J., Illig, T., Klopp, N., et al. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0119-t · Cited by 35
Self-citation
Metadata
- Authors
- Marcus, P. M., Vineis, P., & Rothman, N.
- Venue
- Pharmacogenetics
- Published
- 2000-03
- Volume
- 10
- Issue
- 2
- Pages
- 115-122
- ISSN
- 0960-314X (ISSN-L)
- OpenAlex
- W2063562269
- Cited by
- 166
- References
- 0
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case???control studies conducted in the general population. https://app.cochat.ai/papers/10.1097/00008571-200003000-00003
- The paper
- Marcus, P. M., Vineis, P., & Rothman, N. (2000). NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case???control studies conducted in the general population. Pharmacogenetics. https://doi.org/10.1097/00008571-200003000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.